Boston Herald

Cohan: Combo flu-COVID vax could be game-changer

Moderna, Novavax developing influenza-COVID shot

- ALEXI COHAN

Gaining protection against two awful viruses at one time with a combinatio­n vaccine could mean less pokes in the arm and more convenienc­e in the years to come when we will need it most.

Both Cambridge’s Moderna and Maryland-based vaccine developer Novavax have a combo vaccine in the works to fight influenza and coronaviru­s, two diseases that we know are seasonal and needlessly kill thousands of people.

Moderna’s single-dose booster shot encodes for COVID’s spike protein, and influenza’s proteins as well. The developmen­t was announced by the company’s CEO during an annual research and developmen­t day hosted earlier this week.

Novavax has already started a clinical trial of its combo vaccine in 640 adults age 50 to 70. The vaccine combines two existing shots, Novavax’s NanoFlu and a coronaviru­s vaccine called NVXCoV2373.

Neither of Novavax vaccines has been cleared for use by the FDA yet, though the combo shot showed robust immune responses to both influenza and coronaviru­s in preclinica­l studies, according to the company.

Dr. Alysse Wurcel, an infectious disease physician at Tufts Medial Center, said, “The minute you start combining vaccines, it’s very helpful. … I think combinatio­n vaccines are great.” She noted we already have some combo vaccines, such as a shot for both Hepatitis A and Hepatitis B.

Wurcel said the mRNA technology that has proven to be so successful in beating back coronaviru­s is changing the way we think about vaccines and coming up with new and exciting developmen­ts.

Dr. Jeannie Kenkare, chief medical officer of PhysicianO­ne Urgent Care said anything that makes it easier for patients to get vaccinated is good news.

“A combinatio­n vaccine that will require one injection instead of two means one less needle stick and one less ‘ouchie’ — and who wouldn’t want that,” Kenkare said.

We already know that the flu isn’t going anywhere, and unfortunat­ely we’re learning that coronaviru­s isn’t leaving us either.

Having a combinatio­n shot that could offer protection during peak flu and COVID season could be the wave of the future that has potential to prevent hospitaliz­ation and death in vulnerable people, or even help others get through the winter without being couched for a week or two with terrible symptoms.

As we move forward and hopefully move on from the pandemic, new developmen­ts in vaccinatio­n could start to create a menu of options for folks. We are already seeing it with the choice of three excellent coronaviru­s vaccine options.

The options might be confusing or complicate­d for some, but adding to the menu with things like a combinatio­n vaccine could be helpful in the long run.

The combinatio­n vaccines from Moderna and Novavax won’t hit the market in time for this upcoming flu season, but it’s an exciting developmen­t worth monitoring going forward.

 ??  ??
 ?? NAncY lAnE / HErAlD stAff filE; BElOw, gEttY imAgEs filE ?? ‘VERY HELPFUL’: Cambridge-based Moderna and Maryland-based Novavax, below, are developing a combo vaccine to help thwart influenza and coronaviru­s.
NAncY lAnE / HErAlD stAff filE; BElOw, gEttY imAgEs filE ‘VERY HELPFUL’: Cambridge-based Moderna and Maryland-based Novavax, below, are developing a combo vaccine to help thwart influenza and coronaviru­s.
 ??  ??

Newspapers in English

Newspapers from United States